EA201991113A1 - METHODS OF TREATMENT OF AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF N-OXIDE OF ROFLUMILAST - Google Patents

METHODS OF TREATMENT OF AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF N-OXIDE OF ROFLUMILAST

Info

Publication number
EA201991113A1
EA201991113A1 EA201991113A EA201991113A EA201991113A1 EA 201991113 A1 EA201991113 A1 EA 201991113A1 EA 201991113 A EA201991113 A EA 201991113A EA 201991113 A EA201991113 A EA 201991113A EA 201991113 A1 EA201991113 A1 EA 201991113A1
Authority
EA
Eurasian Patent Office
Prior art keywords
roflumilast
oxide
treatment
autoimmune
inhalation
Prior art date
Application number
EA201991113A
Other languages
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991113A1 publication Critical patent/EA201991113A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)

Abstract

Настоящее описание относится к фармацевтическим композициям (и к способу), пригодным для лечения аутоиммунных, респираторных и/или воспалительных заболеваний и состояний. Способ включает ингаляционное введение N-оксид рофлумиласта субъекту, нуждающемуся в этом. Настоящее описание конкретно относится к лечению астмы и хронического обструктивного заболевания легких (ХОЗЛ) ингаляционным введением N-оксид рофлумиласта.The present description relates to pharmaceutical compositions (and to a method) suitable for the treatment of autoimmune, respiratory and / or inflammatory diseases and conditions. The method includes inhaled administration of roflumilast N-oxide to a subject in need thereof. The present description specifically relates to the treatment of asthma and chronic obstructive pulmonary disease (COPD) by inhalation of roflumilast N-oxide.

EA201991113A 2013-01-28 2014-01-28 METHODS OF TREATMENT OF AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF N-OXIDE OF ROFLUMILAST EA201991113A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN355CH2013 2013-01-28

Publications (1)

Publication Number Publication Date
EA201991113A1 true EA201991113A1 (en) 2019-11-29

Family

ID=68653583

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991113A EA201991113A1 (en) 2013-01-28 2014-01-28 METHODS OF TREATMENT OF AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF N-OXIDE OF ROFLUMILAST

Country Status (1)

Country Link
EA (1) EA201991113A1 (en)

Similar Documents

Publication Publication Date Title
CY1123478T1 (en) METHODS OF INDUCING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF N-OXIDE OF ROFLUMILAST
WO2014031610A8 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EA201791780A1 (en) TIOTROPY INHALATION SOLUTION FOR NONBULIZER SPRAYING
EA201190108A1 (en) PHARMACEUTICAL COMPOSITION FOR INHALATION
GB2496800A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
EA201201397A1 (en) INHALER CONTAINING DISTRIBUTED GLISTER PACKING
EA201590019A1 (en) DRY POWDER INHALERS, CARRIER CONTAINING, EXCELLENT FROM LACTOSE
EA201201395A1 (en) PUSH-BUTTON DEVICE
MX2019013468A (en) Methods for treating chronic obstructive pulmonary disease using benralizumab.
EA201201391A1 (en) INHALER
EA201201392A1 (en) PUSH-BUTTON DEVICE
EA201201393A1 (en) INHALER, DEVELOPED FOR DELIVERY OF MEDICINES AS DRY POWDER
EA201591415A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING MULTICOMPONENT CRYSTALLINE PARTICLES, SUITABLE FOR USE IN INHALATION THERAPY
EA201201389A1 (en) INHALER, CREATING TURBULENCE
MX368036B (en) Inhalable particles comprising tiotropium and indacaterol.
EA201990606A1 (en) SPRAYED THIOTROPY
WO2015049519A3 (en) Method and apparatus for making compositions for pulmonary administration
UA115989C2 (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
EA201991113A1 (en) METHODS OF TREATMENT OF AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF N-OXIDE OF ROFLUMILAST
EA201201394A1 (en) INHALER FOR DELIVERY OF MEDICINE IN THE FORM OF DRY POWDER
EA029678B9 (en) Piperidinium quaternary salts
WO2019098969A3 (en) Dry powder compositions for inhalation
BR112015004810A2 (en) tiotropium preparations
Behmanesh et al. Evaluation of Omeprazole in the Treatment of Moderate to Severe Persistent Asthma in Children
MX2019009243A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.